With pivot to less-rare diseases, Alexion needs a new sticker-price plan, CEO says

Published: 9/01/2019
With pivot to less-rare diseases, Alexion needs a new sticker-price plan, CEO says
Source: WWW.FIERCEPHARMA.COM

Alexion's Soliris is among the world's priciest drugs, but as it transforms from an ultrarare-disease company to a rare-disease company, its pricing will have to change, too. “This is a story about innovation and volume," CEO Ludwig Hantson said. "It is not going to be a story about price."

Read more
Related news
Comment
Latest in blog
FACEBOOK